Medical Definition of Patent ductus arteriosus
Patent ductus arteriosus: Failure for the ductus arteriosus, an arterial shunt in fetal life, to close on schedule.
Before birth, blood pumped from the heart through the pulmonary artery toward the lungs is shunted into the aorta. This arterial shunt is a short vessel called the ductus arteriosus. When the shunt is open, it is said to be patent
The ductus arteriosus usually closes at or shortly after birth, permitting blood from that moment on to course from the heart directly to the lungs. However, if the ductus arteriosus remains open (patent), flow reverses and blood from the aorta is shunted left-to-right into the pulmonary artery and thence recirculated through the lungs.
Patent ductus arteriosus (PDA) is a particularly common problem in premature infants with the respiratory distress syndrome. The left-to-right shunt through the ductus increases their risk of serious complications including brain hemorrhage.
A PDA may close spontaneously (on its own). If not, it needs to be prompted pharmacologically to close and, if that does not work, it must be ligated (tied off) surgically.
IV indomethacin (Indocin) was the conventional therapy to promote closure of PDA in premies but indomethacin affects blood flow to organs such as the kidney and so may lead to complications such as renal failure. Ibuprofen (the active ingredient in Advil, Motrin, Medipren and Nuprin) has been found to work as well as indomethacin in treating PDA in preterm infants with the respiratory distress syndrome and is less likely to impair their kidney function.
Dr. Robert E. Gross at Boston Children's Hospital in 1939 devised the surgical approach to correcting patent ductus arteriosus by ligating it.Source: MedTerms™ Medical Dictionary
Last Editorial Review: 6/9/2016
Top RxList Drug News
- MI Linked to Increased Vascular Dementia, Not Alzheimer's
- New Guidelines Released on Pediatric Obesity and Stigma
- FDA Expands Approval of Sutent to Reduce the Risk of Kidney Cancer Returning
- FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
- FDA Approves Treatment for Rare Genetic Enzyme Disorder
Find out what women really need.